BIOPOR Bioporto A/S

BioPorto to Participate in H.C. Wainwright’s 24th Annual Global Investment Conference

BioPorto to Participate in H.C. Wainwright’s 24th Annual Global Investment Conference

COPENHAGEN, Denmark and BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced plans to participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York City.

Following are details for management’s presentation:

        Date: September 12, 2022

        Time: Available On Demand at 7am ET

        Webcast Link:

Management will also be available for 1x1 meetings. To request a meeting please contact: or . Following the conference, the presentation video will be available for three months on BioPorto’s website at .

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship product is The NGAL Test, which has been designed to aid in the risk assessment of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The NGAL Test is CE marked and registered in a number of countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit .

For further information, please contact:

EU Investor Relations

Tim Eriksen

Zenith Advisory



US Investor Relations

Ashley Robinson

LifeSci Advisors





EN
08/09/2022

Underlying

BIOPORBioporto A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Ændringer i selskabets Direktion

Ændringer i selskabets Direktion 11. december 2025 Meddelelse nr. 29 Ændringer i selskabets Direktion KØBENHAVN, DANMARK og BOSTON, MA, USA, 11. december 2025 (GLOBE NEWSWIRE) – BioPorto A/S ("BioPorto") (CPH:BIOPOR) meddelte i dag, at Niels Høy Nielsen har opsagt sin stilling som CFO for BioPorto for at tiltræde en CFO-stilling i et andet selskab. "Jeg har værdsat det tætte samarbejde med Niels i de sidste par måneder, siden jeg tiltrådte min stilling i BioPorto. Niels har ydet vigtige bidrag til virksomheden og jeg ønsker ham alt det bedste i hans fremtidige stilling," sagde Carsten B...

December 11, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Changes to the Executive Management

Changes to the Executive Management December 11, 2025 Announcement no. 29                                                                          Changes to the Executive Management COPENHAGEN, DENMARK and BOSTON, MA, USA, December 11, 2025 (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto”) (CPH:BIOPOR) announced today that Niels Høy Nielsen has resigned as CFO of BioPorto to become CFO at another company. “I have valued the close collaboration with Niels during the last couple of months since I joined BioPorto. He has made important contributions across the company and wish him all the bes...

December 11, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Ledende medarbejderes transaktioner

Ledende medarbejderes transaktioner 24. november 2025Meddelelse nr. 28                                                                          Ledende medarbejderes transaktioner I forbindelse med gennemførelsen af BioPorto A/S' rettede emission, som beskrevet i selskabsmeddelelse nr. 27, har BioPorto A/S i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget indberetning af nedenstående transaktioner vedrørende aktier i BioPorto A/S foretaget af personer med ledelsesansvar i BioPorto A/S og/eller nærtstående til disse. 1 Nærmere oplysninger om personen med ledelsesansvar/pers...

November 24, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Managers’ transactions

Managers’ transactions  November 24, 2025Announcement no. 28                                                                          Managers’ transactions In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 27, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them. 1 Details of the person discharging managerial responsi...

November 24, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto A/S rejser ca. 43 mio. kr. i ny kapitalrunde - Ændring i anta...

BioPorto A/S rejser ca. 43 mio. kr. i ny kapitalrunde - Ændring i antal aktier og stemmer 24. november 2025 Meddelelse nr. 27                                                                          BioPorto A/S rejser ca. 43 mio. kr. i ny kapitalrunde - Ændring i antal aktier og stemmer Gennemførelse af kapitalforhøjelse København, Danmark, 24. november 2025, (GLOBE NEWSWIRE) - Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) besluttede den 13. november 2025 at gennemføre en rettet emission af 40.438.426 nye aktier til eksisterende større aktionærer, nye instit...

November 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch